PUBLIC CONTRACT · 2018
EMTRICITABINA+TENOFOVIR ALAFENAMIDA, OR, 200+25MG; COMP e 200+ 10MG e EMTRICITABINA + RILPIVIRINA + TENOFOVIR ALAFENAMIDA [200 + 25 + 25 MG; COMP] para 2018 ao abrigo do AQ 2017/61
- Contract value
- €136,220.40
- Signed on
- 16 April 2018
- Procedure
- Ao abrigo de acordo-quadro (art.º 259.º)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 4421358PUBLISHED DESCRIPTION
NL-508-2018 Aquisição de EMTRICITABINA+TENOFOVIR ALAFENAMIDA, OR, 200+25MG; COMP e 200+ 10MG e EMTRICITABINA + RILPIVIRINA + TENOFOVIR ALAFENAMIDA [200 + 25 + 25 MG; COMP] para 2018 ao abrigo do AQ 2017/61
Parties involved
- Place of performance
- Portugal, Lisboa, Amadora
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- GILEAD SCIENCES, LDA · Tax ID 503604704
Values and timeline
- Contract price
- €136,220.40
- Procedure base price
- €136,220.40
- Total effective price
- Not reported on Portal BASE
- Publication date
- 19 April 2018
- Award date
- 11 April 2018
- Signing date
- 16 April 2018
- Performance period
- 259 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Ao abrigo de acordo-quadro (art.º 259.º)
- Award criterion
- Not stated
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- Artigo 259.º do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL 18/2008)
- Framework agreement
- CP 2017/61 - Acordo quadro para fornecimento de Medicamentos Diversos às Instituições e Serviços do Serviço Nacional de Saúde
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 3353915
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.